Durect Overview
- Year Founded
-
1998
- Status
-
Acquired/Merged
- Employees
-
13
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$434M
Durect General Information
Description
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.
Contact Information
Website
www.durect.comCorporate Office
- 10240 Bubb Road
- Cupertino, CA 95014-4166
- United States
Corporate Office
- 10240 Bubb Road
- Cupertino, CA 95014-4166
- United States
Durect Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Merger/Acquisition | 11-Sep-2025 | $434M | Completed | Generating Revenue | ||
| 12. 2PO | 20-Jul-2023 | Completed | Generating Revenue | |||
| 11. PIPE | 08-Feb-2023 | Completed | Generating Revenue | |||
| 10. 2PO | 07-Feb-2023 | Completed | Generating Revenue | |||
| 9. 2PO | 15-Apr-2016 | Completed | Generating Revenue | |||
| 8. PIPE | 01-Jul-2010 | Completed | Generating Revenue | |||
| 7. PIPE | 18-Sep-2009 | Completed | Generating Revenue | |||
| 6. IPO | 28-Sep-2000 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 28-Mar-2000 | $25M | $60.8M | Completed | Generating Revenue | |
| 4. Early Stage VC (Series B1) | 01-Oct-1999 | $699K | $35.8M | Completed | Product Development |
Durect Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B1 | ||||||||
| Series B | ||||||||
| Series A2 | 8,641,867 | $0.000100 | $0.05 | $1.09 | $1.09 | 1x | $1.09 | 22.27% |
| Series A1 | 5,600,000 | $0.000100 | $0.05 | $1 | $1 | 1x | $1 | 14.43% |
Durect Comparisons
Industry
Financing
Details
Durect Competitors (44)
One of Durect’s 44 competitors is Novartis, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis | Corporation | Basel, Switzerland | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Sun Pharmaceutical Industries | Corporation | Mumbai, India | ||||
| Alkermes | Formerly VC-backed | Dublin, Ireland | ||||
| Otsuka Holdings | Corporation | Tokyo, Japan |
Durect Patents
Durect Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025101669-A1 | Treatment of alcohol-associated hepatitis | Inactive | 07-Nov-2023 | ||
| AU-2023411014-A1 | 25-hydroxy-cholest-5-en-3-sulfate choline, formulations thereof and methods for preparing, and medical uses of same | Pending | 23-Dec-2022 | ||
| EP-4637722-A1 | 25-hydroxy-cholest-5-en-3-sulfate choline, formulations thereof and methods for preparing, and medical uses of same | Pending | 23-Dec-2022 | ||
| WO-2024138203-A1 | 25-hydroxy-cholest-5-en-3-sulfate choline, formulations thereof and methods for preparing, and medical uses of same | Inactive | 23-Dec-2022 | ||
| AU-2022491085-A1 | Salts including crystalline salts of 25-hydroxy-cholest-5-en-3-sulfate and methods for preparing same | Pending | 23-Dec-2022 | C07J31/006 |
Durect Signals
Durect Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Azimuth Opportunity | Investment Bank | Minority | ||
| Bain Capital Public Equity | Hedge Fund | Minority | ||
| CHL Medical Partners | Venture Capital | Minority | ||
| Premier Medical Partner Fund | Venture Capital | Minority | ||
| Venrock | Venture Capital | Minority |
Durect Acquisitions (2)
Durect’s most recent deal was a Merger/Acquisition with Southern BioSystems for . The deal was made on 30-Apr-2001.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Southern BioSystems | 30-Apr-2001 | Merger/Acquisition | Drug Delivery | ||
| ALZET | 01-Jan-2000 | Merger/Acquisition | Therapeutic Devices |
Durect ESG
Risk Overview
Risk Rating
Updated February, 28, 2026
40.27 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Pharmaceuticals
Subindustry
of 406
Rank
Percentile
Durect FAQs
-
When was Durect founded?
Durect was founded in 1998.
-
Where is Durect headquartered?
Durect is headquartered in Cupertino, CA.
-
What is the size of Durect?
Durect has 13 total employees.
-
What industry is Durect in?
Durect’s primary industry is Drug Discovery.
-
Is Durect a private or public company?
Durect is a Private company.
-
What is the current valuation of Durect?
The current valuation of Durect is .
-
What is Durect’s current revenue?
The current revenue for Durect is .
-
How much funding has Durect raised over time?
Durect has raised $253M.
-
Who are Durect’s investors?
Azimuth Opportunity, Bain Capital Public Equity, CHL Medical Partners, Premier Medical Partner Fund, and Venrock are 5 of 6 investors who have invested in Durect.
-
Who are Durect’s competitors?
Novartis, Cipla, Sun Pharmaceutical Industries, Alkermes, and Otsuka Holdings are some of the 44 competitors of Durect.
-
When was Durect acquired?
Durect was acquired on 11-Sep-2025.
-
Who acquired Durect?
Durect was acquired by Bausch Health Companies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process